Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYL1601
- Development stage
- Unknown
- Lead developer
- Sylentis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic
01
Overview
SYL1601 is a small interfering RNA (siRNA) therapeutic candidate developed by Sylentis (a subsidiary of PharmaMar) for the treatment of inflammatory ocular conditions, most notably dry eye disease. The drug functions through the RNA interference (RNAi) mechanism, specifically targeting the messenger RNA (mRNA) of the Tumor Necrosis Factor Receptor 1 (TNFR1). By promoting the degradation of TNFR1 mRNA, SYL1601 reduces the density of TNFR1 receptors on the ocular surface, thereby inhibiting the pro-inflammatory signaling cascade initiated by Tumor Necrosis Factor-alpha (TNF-alpha). This targeted approach aims to alleviate the symptoms of pain and inflammation associated with chronic dry eye without the systemic side effects often seen with broader anti-inflammatory agents.
- Other names
- TNFR1 small interfering RNATNFR-1 small interfering RNATNFR 1 small interfering RNATNFR1-siRNATNFR-1-siRNATNFR 1-siRNA
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on SYL1601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYL1601.